Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051239 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL6448846 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL1915651 | 0.91 | CA2 (0.55) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL1915653 | 0.91 | CA2 (0.55) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL6161042 | 0.89 | GRIK1 (0.49) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL6161064 | 0.89 | GRIK1 (0.49) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL8217023 | 0.88 | GRIK1 (0.50) | MEN1GAAKMT2ASLC1A2SLC1A1 | |
| SCHEMBL6808467 | 0.88 | GRIK1 (0.50) | MEN1GAAKMT2ASLC1A2SLC1A1 | |
| SCHEMBL7069281 | 0.88 | GRIK1 (0.50) | MEN1GAAKMT2ASLC1A2SLC1A1 | |
| SCHEMBL7075183 | 0.88 | GRIK1 (0.50) | MEN1GAAKMT2ASLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110358752-A | A kind of Aspergillus oryzae lipase and preparing the application in Bu Waxitan chiral intermediate | 浙江工业大学 | 2019-10-22 | — | — | CN | claimed |
| WO-2018220646-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL] BUTANAMIDE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-12-06 | — | — | WO | claimed |
| CN-115286504-B | Method for synthesizing (R) -2- (2- (tert-butoxy) -2-oxyethyl) pentanoic acid | 上海博氏医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-115286504-A | Method for synthesizing (R) -2- (2- (tert-butoxy) -2-oxyethyl) pentanoic acid | 上海博氏医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-111675643-B | Preparation method of brivaracetam | 浙江天宇药业股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-20210163410-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL] BUTANAMIDE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-06-03 | — | — | US | disclosed |
| WO-2018220646-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL] BUTANAMIDE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-12-06 | — | — | WO | disclosed |
| EP-3077401-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9867833-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-2897938-B1 | FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-3077401-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| CN-106008411-A | Method for preparing chiral 4-substituted dihydrofuran-2(3H)-ketone | 上海华默西医药科技有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| WO-2015085007-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | HDAC1 530/4885HDAC2 2194/4885CHRM1 583/4885 |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | HDAC1 530/4885HDAC2 2194/4885CHRM1 583/4885 |
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | HDAC1 1035/4885HDAC2 1649/4885CHRM1 3401/4885 |
| US-20210163410-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL] BUTANAMIDE AND ITS INTERMEDIATES THEREOF | SCN1B, CACNA1B, CACNA1D | HDAC1 519/4885HDAC2 517/4885CHRM1 745/4885 |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | HDAC1 1035/4885HDAC2 1649/4885CHRM1 3401/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | HDAC1 530/4885HDAC2 2194/4885CHRM1 583/4885 |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | HDAC1 1035/4885HDAC2 1649/4885CHRM1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.